Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Does Alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women

Study (reference) Sample (ALN*/ control) and duration Inclusion criteria Age (years) (SD‡) Percentage prevalent vertebral fractures (VF, %) Intervention/ Control Blinding, randomization Loss to follow-up or withdrew from study (n/N) (%)
Orwoll 2000 [11] 146/95 (2 years) Men with BMD† T-score = -2 at femoral neck and T-score = -1 at the lumbar spine; OR Men with T-score = -1 at the femoral neck and at least one vertebral or osteoporotic fracture ALN: Mean age 63 (13) 49% VF Control: Mean age 63 (12) 52% VF ALN*: 10 mg + 500 mg Calcium + 400–450 IU Vitamin D Control: 500 mg Calcium + 400–450 IU Vitamin D - Double-blind - Radiologists reading vertebral x-rays blinded to intervention -Method of randomization unclear 38/241 (15.8%)
Ringe 2004 [12] 68/66 (3 years) Men with BMD† T-score = -2.5 at femoral neck or lumbar spine, excluding hypogonadal men ALN*: Mean age 52.7 (11.1) 54% VF Control: Mean age 53.3 (10.9) 53% VF ALN*: 10 mg + 500 mg Calcium Control: 500 mg Calcium + 1 μg alfacalcidiol - Open-label - Radiologists reading vertebral x-rays blinded to intervention -Method of randomization unclear 16/134 (11.9%)
  1. *ALN, alendronate (daily dose)
  2. \dagBMD, bone mineral density measurement by dual X-ray absorptiometry, compared to young adult male peak bone mass
  3. \ddagSD, Standard deviation